Investorideas.com newswire, breaking biotechnology and pharma news

Tuesday, December 13, 2011

Biotech Trading News Alert: Aethlon Medical (OTCBB: AEMD) Trades Up over 9% on News of HIV-AIDS Research Discovery

Point Roberts, WA - December 13, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for Aethlon Medical, Inc. (OTCBB:AEMD) following news of its HIV-AIDS research discovery. The stock is trading up over 9% on 160,000 shares in morning trading.
Investorideas.com Newswire Aethlon Medical, Inc. (OTCBB:AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS). The Aethlon Hemopurifier® is a first-in-class therapeutic device that selectively targets the clearance of viruses, immunosuppressive proteins, and disease enhancing exosomes from the entire the entire circulatory system.
Full news: http://finance.yahoo.com/news/Aethlon-Medical-Announces-HIV-prnews-3930211403.html?x=0
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Contact:
James A. Joyce
Chairman and CEO
858.459.7800 x301
learn more about OTCBB: AEMD
http://www.investorideas.com/CO/AEMD/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get free investor news and stock alerts
Sign Up:  http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclosure/ disclaimer: Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All information published is from public filings, news, SEC filings and or company comments and quotes. AEMD has paid Investorideas.com four thousand for the email distribution and online distribution of this release through its network including Stock Profiler and Investorideas.com growing network of online financial media.
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

No comments:

Post a Comment